Cisplatin and etoposide in oesophageal cancer: A phase II study

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 980-984

  Kok, T C ^a   Van Der Gaast, A ^a   Dees, J ^a   Eykenboom, W M H ^a   Van Overhagen, H ^a   Stoter, G ^a   Tilanus, H W ^a   Splinter, T A W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antineoplastic agent; Cisplatin; Epidermoid cancer; Etoposide; Oesophageal neoplasm

Indexed keywords

ANTINEOPLASTIC ALKALOID; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; ESOPHAGUS CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VOMITING;

EID: 0029737060     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.469     Document Type: Article

References (36)

1. ACHTERRATH W, NIEDERLE N, RAETTIG R AND HILGARD P. (1982). Etoposide-chemistry, preclinical and clinical pharmacology. Cancer Treat. Rev., 9 (suppl. A), 3-13.
2. AGHA FP, GENNIS MA, ORRINGER MB AND FORASTIERE AA. (1986). Evaluation of response to preoperative chemotherapy in esophageal and gastric cardia cancer using biphasic esophagrams and surgical-pathologic correlation. Am. J. Clin. Oncol. (CCT), 3, 227-232.
3. AJANI JA. (1994). Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin. Oncol., 21, 474-482.
4. AJANI JA, ILSON D, DAUGHERTY K, PAZDUR R, LYNCH PM AND KELSEN DP. (1994). Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl Cancer Inst., 86, 1086-1091.
5. BLEIBERG H, JACOB JH, BEDENNE L, PAILLOT B, DE BESI P AND LACAVE A. (1991). Randomized phase II trial of 5-fluorouracil and cisplatin (DDP) versus DDP alone in advanced oesophageal cancer. Proc. Am. Soc. Clin. Oncol., 10, 145.
6. CAPPELAERE P, GUIOCHET N, BASTIT P, FAVRE R, VANDERBURG M, GOUPIL A, CHAUVERGNE J, THOMAS D, VAN GLABBEKE M AND ARMAND JP. (1993). Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung. Eur. J. Cancer, 29A, 1216.
7. CAVALLI F, SONNTAG RW, JUNGI F, SENN HJ AND BRUNNER KW. (1978). VP-16-213 monotherapy for remission induction of small-cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat. Rep., 62, 473-475.
8. CHEN GL, YANG L, ROWE TC, HALLIGAN BD, TEWEY KM AND LIU LF. (1984). Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem., 259, 13560-13566.
9. CLARK PI. (1992). Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin. Oncol., 19 (suppl. 6), 20-27.
10. CONROY T, ETIENNE PL, ADENIS A, FRANCOIS E, WAGENER DJTH, PAILLOT B, WILS J, DELGADO FM, MERLE S, VAN POTTELSBERGHE C AND BLEIBERG H. (1993). Vinorelbine (Navelbine}®): a promising drug in metastatic epidermoid esophageal carcinoma. Proc. Am. Soc. Clin. Oncol., 12, 191.
11. COONLEY CJ, BAINS M, HEELAN R, DUKEMAN M AND KELSIN DP (1983). Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat. Rep., 67, 397-398.
12. DAVIS S, SHANMUGATHASA M AND KESSLER W. (1980). Cisdichlorodiammine-platinum(II) in the treatment of esophageal carcinoma. Cancer Treat. Rep., 64, 709-711.
13. DE BESI P, SILENI VC, SALVAGNO L, TREMOLADA C, CARTEI G, FOSSER V, PACCAGNELLA A, PERACCHIA A AND FIORENTINO M. (1986). Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. Cancer Treat. Rep., 70, 909-910.
14. DINWOODIE WR, BARTOLUCCI AA, LYMAN GH, VELEZ-GARCIA E, MARTELO OJ AND SARMA PR. (1986). Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group trial. Cancer Treat. Rep., 70, 267-270.
15. ENGSTROM PF, LAVIN PT AND KLAASEN DJ. (1983). Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat. Rep., 67, 713-715.
16. HARSTRICK A, BOKEMEYERE C, PREUSSER P, KÖHNE-WÖMPNER CH, MEYER H-J, STAHL M, KNIPP H, SCHMOLL H-J AND WILKE H. (1992). Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother. Pharmacol., 29, 321-322.
17. HAYASHI K, IDE H, SHINODA M AND FUKUSHIMA M. (1992). Phase II study of cisplatin plus 5-fluorouracil and leucovorin for squamous cell carcinoma of the esophagus. Proc. Am. Soc. Clin. Oncol., 11, 178.
18. IIZUKA T, KAKEGAWA T, IDE H, ISONO K, TAKAGI I, FUKUSHIMA M, ANDO N, WATANABE H, TAKIYAMA W, ARIMORI M, ISHIDA K AND ENDO M. (1991). Phase II study of CDDP+5-FU for squamous esophageal carcinoma: JEOG Cooperative Study results. Proc. Amer. Soc. Clin. Oncol., 10, 157.
19. KELSEN D, HIEARIS B, COONLEY C, CHAPMAN R, LESSER M, DUKEMAN G, HEELAN R AND BAINS M. (1983). Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma. Am. J. Med., 75, 645-652.
20. KELSEN DP, MINSKY B, SMITH M, BEITLER J, NIEDZWIECKI D, CHAPMAN D, BAINS M, BURT M, HEELAN R AND HILARIS B. (1990). Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. J. Clin. Oncol., 8, 1352-1361.
21. KOK TC, SPLINTER TAW AND VERWEIJ J. (1988). Etoposide and cisplatin in advanced esophageal cancer. A preliminary report. Acta Oncol., 27, 807-809.
22. LONG BH, MUSIAL ST AND BRATTAIN MG. (1985). Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res., 45, 3106-3112.
23. MANNELL A AND WINTERS Z. (1989). Carboplatin in the treatment of esophageal cancer. S. Afr. Med. J., 76, 213-214.
24. MÜLLER JM, ERASMI H, STELZNER M, ZIEREN U AND PICHLMAIER H. (1990). Surgical therapy of oesphageal carcinoma. Br. J. Surg., 77, 845-857.
25. PANETTIERRE FJ, LEICHMAN LP, TILCHEN EJ AND CHEN TT. (1984). Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study. Cancer Treat. Rep., 68, 1023-1024.
26. RADICE PA, BUNN JR PA AND IHDE DC. (1979). Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, Non-Hodgkin's lymphomas, and other malignancies. Cancer Treat. Rep., 63, 1231-1239.
27. RAVRY MJR, MOORE MR, OMURA GA, ESSEESE I AND BARTOLUCCT A. (1985). Phase II evaluation of cisplatin in squamous carcinoma of the esophagus: a South-eastern Cancer Study Group Trial. Cancer Treat. Rep., 69, 1457-1458.
28. ROSS W, ROWE T, GLISSON B, YALOWICH J AND LIU L. (1984). Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res., 44, 5857-5860.
29. ROTH JA, LICHTER AS, PUTNAM JB JR AND FORASTIERE AA. (1993). Cancer of the esophagus. In Cancer: Principles and Practice of Oncology, DeVita VT Jr. Hellman SA, Rosenberg SA (eds) pp.{T#}776 817. Lippincott: Philadelphia.
30. SLEVIN ML, CLARK PI, JOEL SP, MALIK S, OSBORNE RJ, GREGORY WM, LOWE DG, REZNEK RH AND WRIGLEY PFM. (1989). A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol., 7, 1333 -1340.
31. SPIELMANN M, PAILLOT B, KAC J, KAYITALIRE L, BARDON M. GUILLOT T, QUEUNIET AM AND TURSZ T. (1993). Cisplatin and 5-fluorouracil modulated by the pure L stereoisomer of folinic acid in continuous infusion for treatment of patients with esophageal squamous cell carcinomas: a phase I/II study. Proc. Amer. Soc. Clin. Oncol., 12, 196.
32. SPLINTER TAW, KOK TC, KHO S, LAMERIS H. TEN KATE F, DALESIO O, DOLMAN B, PALMEN F, BOUVY J, BURGHOUTS J, SIMONIS F, HARPER P, RANKIN E, VAN REIJSWOUD I AND VAN HOOGENHUlJZE J. (1986). A multicentre phase II trial of cisplatin and (oral) vepesid in inoperable non-small cell cancer of the lung. Semin. Oncol., 13 (suppl. 3), 97-103.
33. STEEL A, CULLEN MH, ROBERTSON PW AND MATTHEWS HR. (1988). A phase II study of carboplatin in adenocarcinoma of the esophagus. Br. J. Cancer, 58, 500-501.
34. STERNBERG C, KELSEN D, DUKEMAN M, LEICHMAN L AND HEELAN R. (1985). Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer Treat. Rep., 69, 1305-1307.
35. VISSER O, COEBERGH JWW AND SCHOUTEN LJ. (1990). Incidence of Cancer in the Netherlands: Fourth Report of the Netherlands Cancer Registry. Association of Comprehensive Cancer Centres: Utrecht.
36. WORLD HEALTH ORGANIZATION. (1979). WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva.